Dosage of intrathecal Baclofen maintenance therapy in the spastic syndromes

Journal Medical Libanais

Volumn 52, Issue 1, 2004, Pages 13-18

  Fares, Youssef ^a   Khazim, Rabi M ^b   Del Barrio, E R ^b   Burzaco, J A ^b  

^a Hammoud Hospital   (Lebanon)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN;

ADULT; AGITATION; ANXIETY; ARTICLE; CEREBELLUM DISEASE; CERVICAL MYELOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; INFUSION PUMP; MALE; MULTIPLE SCLEROSIS; SPASTIC PARESIS; SPASTICITY; URTICARIA;

ADULT; BACLOFEN; CEREBRAL PALSY; CERVICAL VERTEBRAE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MALE; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; OUTPATIENTS; PARAPLEGIA; PATIENT SELECTION; SPINAL CORD DISEASES; SUBARACHNOID SPACE; TIME FACTORS;

EID: 14644417846     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Enna SJ, Gallagher JP. Biochemical and electrophysiological characteristics of mammalian GABA receptors. Int Rev Neurobio 1983; 12: 181-212.
2. Krnjevic K. Chemical nature of synaptic transmission in vertebrates. Physiol Rev 1974; 54: 418-540.
3. Simmonds MA. Physiology and pharmacological characterization of the actions of GABA. In: Bowery NG, editor. Actions and interactions of GABA and benzodiazepines. New York: Raven Press, 1984: 27-41.
4. Curtis DR, Johnston GAR. Amino acid transmitters in the mammalian central nervous system. Ergeb Physiol 1974; 69: 97-188.
5. Davidoff RA, Sears ES. The effects of Lioresal on synaptic activity in the isolated spinal cord. Neurology 1974; 24: 957-63.
6. Duncan GW, Shahani BT, Young R. An evaluation of Baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology 1987; 26: 41-6.
7. Lazorthes Y. Neuropharmacologie en application intrathécale. Neurochirurgie 1985; 31 (Suppl 1): 95-101.
8. Schwartz ML, Zheng DS, Goldman-Rkic PS. Periodicity of GABA-containing cells in primate prefrontal cortex. J Neurosci 1988; 8: 1962-70.
9. Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal Baclofen for intractable axial dystonia. Neurology 1991; 41: 1141-2.
10. Faigle JW, Keberle H. The metabolism and pharmacokinetics of Lioresal. In: Birkmayer W, editor. Spasticity - A Topical Survey. Vienna: Hans Huber Publishers, 1972: 94.
11. Price GW, Wilkin GP, Turnbull MJ, Bowery NG. Are the Baclofen sensitive GABA B receptors present on primary afferent terminals of the spinal cord? Nature 1984; 307: 71-4.
12. Penn RD, Kroin JS. Continuous intrathecal Baclofen for severe spasticity. Lancet 1985; 125: 127.
13. Ashworth B. Preliminary trial of Carisprodol in multiple sclerosis. Practitioner 1964; 192: 540-3.
14. Fares Y, del Barrio ER, Burzaco JA. El uso intratecal de Baclofen en el tratamiento de la espasticidad rebelde. Modos y resultados. Dolor 1999; 14: 69-79.
15. Van Schaeybroeck P, Nuttin B, Lagae L, Schrigvers E, Barghgraef C, Fays P. Intratechal Baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 2000; 46 (3): 603-9.
16. Penn RD. Intrathecal Baclofen for spasticity of spinal origin: Seven years of experience. J Neurosurg 1992; 77: 236-40.
17. Penn RD, Kroin JS. Intrathecal Baclofen alleviates spinal cord spasticity. Lancet 1984; 1 (8385): 1078.
18. Costas A, Jhon P. Effect of Baclofen on gait in spastic MS patients. Acta Neurol Scand 2000; 101 (4): 244-8.
19. Dario A, Distefano MG, Grossi A, Casagrande F, Bono G. Long-term intrathecal Baclofen infusion in supraspinal spasticity of adulthood. Acta Neurol Scand 2002; 105 (2): 83-7.
20. Young RR. Treatment of spastic paresis. NEJM 1989; 320: 1553-5.
21. Penn RD, Kroin JS. Long term of intrathecal Baclofen infusion for the treatment of spasticity. J Neurosurg 1987; 66: 181-5.
22. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R, Carillo JP. Chronic intrathecal Baclofen administration for control of severe spasticity. J Neurosurg 1990; 72: 393-402.
23. Muller H, Zierski J, Dralle D, Hoffman O, Michaellis G. Intrathecal Baclofen in spasticity. In: Muller H, Zierski J, Penn RD, editors. Local Spinal Therapy of Spasticity. Springer-Verlag, 1988, 155-214.
24. Sedan R, Lazorthes Y. La neurostimulation électrique thérapeutique. Neurochirurgie 1978; 24 (Suppl 1): 1-125.
25. Siegfried J, Lazorthes Y. La neurochirurgie fonctionnelle de l'infirmité motrice d'origine cérébrale. Neurochirurgie 1985; 31 (Suppl 1): 1-118.
26. Ochs G, Strumppler A, Meyerson B et al. Intrathecal Baclofen for long term treatment of spasticity; A multicenter study. J Neurol Neurosurg Psych 1989; 52: 933-9.
27. Detrembleur C, Plaghki L. Quantitative assessment of intrathecally administered Baclofen in spasticity. Arch Phys Med Rehab 2000; 81: 279-84.
28. Broseta J, Morales F, Garcia-March G et al. Use of Intrathecal Baclofen administered by programmable infusion pumps in resistent spasticity. Acta Neurochirugia 1989; 46: 39-45.
29. Stempien L, Tsai T. Intrathecal Baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehab 2000; 79 (6): 536-41.
30. Latash MI, Penn RD, Corcos DM, Gottlieb GL. Effects of intrathecal Baclofen on voluntary motor control in spastic paresis. J Neurosurg 1990; 72: 388-92.
31. Latash ML, Penn RD, Corcos DM, Gottieb GL. Short-term effects of intrathecal Baclofen in spasticity. Exp Neurol 1989; 103: 165.
32. Penn RD, Savoy SM, Corcos D et al. Intrathecal Baclofen for severe spasticity. NEJM 1989; 320: 1517-21.
33. Taveira da Silva A. Letter: Intrathecal Baclofen. NEJM 1989; 321: 1414.